Kaul S, Gosmanova EO, Castriota F, Hitchens A, Candrilli S, Parikh R, Esterberg E, Ayodele O. Recent trends in hypoparathyroidism-related inpatient and emergency department admissions and costs in the United States. J Endocr Soc. 2023 Apr 18;7(5):bvad050. doi: 10.1210/jendso/bvad050.
Ervin C, Joish VN, Castro C, DiBenedetti D, Evans E, Carroll A, Lapuerta P. Elevating the patient voice in type 1 diabetes clinical trials: a comparison of in-depth exit interviews and diabetes-specific questionnaires. Poster presented at the 2020 Endocrine Society Conference (ENDO2020) (Conference cancelled); March 2020. San Francisco, CA. [abstract] J Endocr Soc. 2020 May 8; 4(Suppl 1):MON-630. doi: 10.1210/jendso/bvaa046.1290
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.